Nov 17, 2025 · Avalo is a clinical-stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead asset, AVTX-009, …

At Avalo, we’re 100% focused on developing treatments for immune-mediated inflammatory diseases with large unmet needs that affect millions worldwide. Our strategy is to develop …

Nov 6, 2025 · Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, …

Progressing product candidates targeting immune-mediated inflammatory diseases We are advancing a pipeline that emphasizes a high-value, potentially best-in-class and best-in …

Jun 23, 2025 · Oct 29, 2025 7:00 am EDT Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Rusty the Cavapoo is wagging his way up the corporate ladder at Avalo. He joined the company as Mascot in 2022 and, given his impressive in-office accomplishments, his recent promotion …

Oct 8, 2024 · Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, …

Jun 30, 2025 · Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead …

Nov 17, 2025 · Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead …

Mar 27, 2024 · Avalo’s current leadership team will continue to lead Avalo and no person affiliated with AlmataBio will become an officer or employee of Avalo. Pursuant to the acquisition, …